Cite
HARVARD Citation
Bazinet, A. et al. (2022). Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study. Lancet. 9 (10), pp. e756-e765. [Online].